BiotechTube

liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + Bevacizumab

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
40
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malignant Ascites

Conditions

Malignant Ascites

Trial Timeline

Nov 28, 2025 → Jun 30, 2029

NCT ID
NCT07397819

About liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + Bevacizumab

liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + Bevacizumab is a phase 1/2 stage product being developed by CSPC Pharmaceutical Group Limited for Malignant Ascites. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07397819. Target conditions include Malignant Ascites.

Hype Score Breakdown

Clinical
13
Activity
8
Company
9
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07397819Phase 1/2Recruiting

Competing Products

20 competing products in Malignant Ascites

See all competitors
ProductCompanyStageHype Score
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Tadalafil + GemcitabineEli LillyPhase 1
33
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
41
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
41
DS-1123Daiichi SankyoPhase 1
33
DS-8201aDaiichi SankyoPhase 1
33
DS-5573aDaiichi SankyoPhase 1
33
DS-6051bDaiichi SankyoPhase 1
33
U3-1565Daiichi SankyoPhase 1
33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
41
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
enfortumab vedotinAstellas PharmaPhase 1
33
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
77
Eribulin MesylateEisaiPhase 1
33

Other Products from CSPC Pharmaceutical Group Limited

Butylphthalide + Butylphthalide placeboPhase 3
76
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsPhase 2
51
Sintilimab + Nab paclitaxel + CisplatinPhase 2
51
pegylated liposomal doxorubicin (PLD) + PD-1Phase 2
51